Abiopharma

Interested Person Transaction: Interested Person Transaction pursuant to Catalist Rule 905(2)

IREN Delivers Horizon 1 to Microsoft and Achieves NVIDIA Exemplar Cloud Status on GB300 NVL72

AFC Announces Financial Results for the Second Quarter 2026

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Collegium Announces $50 Million Accelerated Share Repurchase Program

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Rio2 Reports Q2 2026 Financial and Operating Results and Webinar

Yunji to Report First Half 2026 Financial Results on August 20, 2026